文献速递心力衰竭与心肌病

射血分数保留的心力衰竭患者的超声心动图特征

Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

基于PARAGON-HF试验中1097例HFpEF患者的超声心动图数据,分析心脏结构与功能及其与临床结局的关联。中位随访2.8年,288例发生心衰住院或心血管死亡;左室肥厚、E/e'升高、肺动脉收缩压升高和右室舒张末面积增大独立预测复合终点,而左室射血分数和左房大小无显著关联。

要点

  • HFpEF患者中左房扩大(83%)、E/e'升高(53%)和肺动脉高压(31%)常见。
  • 左室质量指数、E/e'、肺动脉收缩压和右室舒张末面积独立预测心衰住院或心血管死亡。
  • 不同HFpEF试验的超声心动图特征存在差异,尽管事件率相似,提示综合征异质性。

核心结论

  • HFpEF患者中舒张功能障碍、左房扩大和肺动脉高压常见。
  • 左室肥厚、左、右侧压力升高和右室扩大独立预测心衰住院或心血管死亡。

研究设计与样本

  • PARAGON-HF试验中,4822例HFpEF患者里1097例在入组6个月内接受超声心动图检查。
  • 采用Cox比例风险模型评估超声指标与首次心衰住院或心血管死亡的关联,校正年龄、性别、入组地区、随机治疗、NT-proBNP和临床危险因素。

主要发现

  • 平均年龄74±8岁,53%为女性,中位NT-proBNP为918 pg/ml(四分位距485至1578 pg/ml),94%有高血压,35%有心房颤动。
  • 平均左室射血分数58.6±9.8%,左室肥厚患病率21%,左房扩大患病率83%,E/e'升高患病率53%,肺动脉高压患病率31%。
  • 中位随访2.8年,288例发生心衰住院或心血管死亡。
  • 完全校正模型中,左室质量指数(每10 g/m2,HR 1.05,95%CI 1.00-1.10,p=0.03)、E/e'(每单位,HR 1.04,95%CI 1.02-1.06,p<0.001)、肺动脉收缩压(每10 mmHg,HR 1.51,95%CI 1.29-1.76,p<0.001)和右室舒张末面积(每cm2,HR 1.04,95%CI 1.01-1.07,p=0.003)与复合终点相关。
  • 左室射血分数和左房大小与复合终点无显著关联(p>0.05)。

临床怎么用

  • 在HFpEF患者中,应关注左室质量指数、E/e'、肺动脉收缩压和右室舒张末面积等超声指标以进行风险分层。
  • 左房大小和左室射血分数在HFpEF中预测价值有限,需结合其他指标综合评估。

局限性

  • 超声检查在入组6个月内进行,未标准化采集时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction) trial tested the efficacy of sacubitril-valsartan in patients with heart failure with preserved ejection fraction (HFpEF). Existing data on cardiac structure and function in patients with HFpEF suggest significant heterogeneity. OBJECTIVES: The aim of this study was to characterize cardiac structure and function, quantify their associations with clinical outcomes, and contextualize these findings with other HFpEF studies. METHODS: Echocardiography was performed in 1,097 of 4,822 PARAGON-HF patients within 6 months of enrollment. Associations with incident first heart failure hospitalization or cardiovascular death were assessed using Cox proportional hazards models adjusted for age, sex, region of enrollment, randomized treatment, N-terminal pro-brain natriuretic peptide, and clinical risk factors. RESULTS: Average age was 74 ± 8 years, 53% of patients were women, median N-terminal pro-brain natriuretic peptide level was 918 pg/ml (interquartile range: 485 to 1,578 pg/ml), 94% had hypertension, and 35% had atrial fibrillation. The mean left ventricular (LV) ejection fraction was 58.6 ± 9.8%, prevalence of LV hypertrophy was 21%, prevalence of left atrial enlargement was 83%, prevalence of elevated E/e' ratio was 53%, and prevalence of pulmonary hypertension was 31%. Heart failure hospitalization or cardiovascular death occurred in 288 patients at 2.8-year median follow-up. In fully adjusted models, higher LV mass index (hazard ratio [HR]: 1.05 per 10 g/m2; 95% confidence interval [CI]: 1.00 to 1.10; p = 0.03), E/e' ratio (HR: 1.04 per unit; 95% CI: 1.02 to 1.06; p < 0.001), pulmonary artery systolic pressure (HR: 1.51 per 10 mm Hg; 95% CI: 1.29 to 1.76; p < 0.001), and right ventricular end-diastolic area (HR: 1.04 per cm2; 95% CI: 1.01 to 1.07; p = 0.003) were each associated with this composite, while LV ejection fraction and left atrial size were not (p > 0.05 for all). Appreciable differences were observed in cardiac structure compared with other HFpEF clinical trials, despite similar E/e' ratio, pulmonary artery systolic pressure, and event rates. CONCLUSIONS: Diastolic dysfunction, left atrial enlargement, and pulmonary hypertension were common in PARAGON-HF. LV hypertrophy, elevated left- and right-sided pressures, and right ventricular enlargement were independently predictive of incident heart failure hospitalization or cardiovascular death. Echocardiographic differences among HFpEF trials despite similar clinical event rates highlight the heterogeneity of this syndrome. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Shah AM, Cikes M, Prasad N, et al. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019. PMID: 31806129. doi:10.1016/j.jacc.2019.09.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。